Dietary supplement in chronic hepatitis C treatment
Phase 2
- Conditions
- Hepatitis C.Chronic viral hepatitis C
- Registration Number
- IRCT2013112915581N1
- Lead Sponsor
- Vice chancellor for research, Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Major criteria to include in the study: The patients with hepatitis C who had not been under therapy were included in the study.
Major criteria to exclude from the study: HIV patients; concurrent infection with hepatitis B and D; alcohol abuse; Wilson’s disease; hemochromatosis; decompensated cirrhosis, child score>9; patients with hepatocellular carcinoma; previous hepatitis C treatment; chronic kidney disorder; using antiepileptic drugs; history of vitamin D consumption (in the control group); pregnancy or breastfeeding; and steroid consumption.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method D Vitamin serum level. Timepoint: At the beginning of treatment and every three months to the end of treatment. Method of measurement: Blood Sampling.;Calcium serum level. Timepoint: At the beginning of treatment and every three months to the end of treatment. Method of measurement: Blood Sampling.
- Secondary Outcome Measures
Name Time Method Quantification of HCV RNA. Timepoint: At weeks 4 and 12 during the treatment period for the assessment of RVR and EVR and at the end of treatment and 24 weeks after. Method of measurement: By Quantitative PCR.